This will take years to occur. Cancer may move along faster, but we’re still waiting to submit the combo BLA, the mom therapy trial protocol still hasn’t been finalized/approved, and GvHD hasn’t started a phase 2 yet.

I can see the market cap increasing sooner and to a higher level if leronlimab works not only in mBC, but other types of metastatic cancer. But, again, the question is what will the FDA want for approval. Will a larger basket trial be sufficient? Or will they ask for a larger, longer trial for each type? We assume the FDA will attempt to move the cancer indication(s) along quickly if results continue to be good, but I said that 5 years ago with early results from combo and mono, but here we sit.